Brief: CytRx Corp Says Arimoclomol Licensee Orphazyme A/S Completes Enrollment In Its Phase 3 Clinical Trial Of Arimoclomol
22/07/2019 14:08
July 22 (Reuters) - CytRx Corp CYTR.PK :
* CYTRX CORPORATION HIGHLIGHTS ARIMOCLOMOL LICENSEE
ORPHAZYME A/S
COMPLETES ENROLLMENT IN ITS PHASE 3 CLINICAL TRIAL OF
ARIMOCLOMOL IN AMYOTROPHIC LATERAL SCLEROSIS
* CYTRX CORP - STUDY ENROLLMENT COMPLETED AHEAD OF SCHEDULE
Source text for Eikon: ID:nPn2PLRv4a
Further company coverage: CYTR.PK
(Reuters.Briefs@thomsonreuters.com)
Recent news on LadRx
See all newsBrief: Ladrx Issues 2024 Update To Shareholders
Brief: LadRx Completes Non-Dilutive Financing Transaction For Up To $11 Mln With Xoma Corporation
Brief: LadRx Intends To Apply To List Stock On Nasdaq Under Symbol 'LADX'
Brief: LadRx Announces Review Of Strategic Alternatives, Provides Corporate Updates
Brief: CytRx Highlights Orphazyme's Update On Productive Meeting With FDA Regarding Arimoclomol In Niemann-Pick Disease Type C